419656
苄哒唑
97%
别名:
2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide, Benzonidazol, N-Benzyl-2-nitroimidazol-1-yl-acetamide
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H12N4O3
化学文摘社编号:
分子量:
260.25
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:
Assay:
97%
InChI
1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)
SMILES string
[O-][N+](=O)c1nccn1CC(=O)NCc2ccccc2
InChI key
CULUWZNBISUWAS-UHFFFAOYSA-N
assay
97%
mp
189-192 °C (lit.)
solubility
methanol: soluble 50 mg/mL, clear, colorless to yellow
functional group
amide, nitro, phenyl
Quality Level
General description
N-Benzyl-2-nitro-1H-imidazole-1-acetamide (Benznidazole) is a nitro-heterocyclic compound. It is widely employed drug for the treatment of Chagas disease. It exhibits three polymorphic forms..
Application
N-Benzyl-2-nitro-1H-imidazole-1-acetamide (Benznidazole) may be used as reference drug for the extraction of guaianolide from the aerial parts of Tanacetum parthenium and to evaluate its in vitro antiprotozoal activity.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Glaucia Vilar-Pereira et al.
Brain, behavior, and immunity, 26(7), 1136-1149 (2012-07-31)
Inflammatory cytokines and microbe-borne immunostimulators have emerged as triggers of depressive behavior. Behavioral alterations affect patients chronically infected by the parasite Trypanosoma cruzi. We have previously shown that C3H/He mice present acute phase-restricted meningoencephalitis with persistent central nervous system (CNS)
Alejandra B Ciccarelli et al.
Antimicrobial agents and chemotherapy, 56(10), 5315-5320 (2012-08-08)
A nutritional characteristic of trypanosomatid protozoa is that they need a heme compound as a growth factor. Because of the cytotoxic activity of heme and its structural similarity to cobalamins, we have investigated the in vitro and in vivo effect
D E Perez-Mazliah et al.
The Journal of antimicrobial chemotherapy, 68(2), 424-437 (2012-10-30)
Even though the use of combined drugs has been proved to be effective in other chronic infections, assessment of combined treatment of antiparasitic drugs in human Chagas' disease has not been performed. Herein, a pilot study was conducted to evaluate
Israel Molina et al.
The New England journal of medicine, 370(20), 1899-1908 (2014-05-16)
Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtimox, which have been associated with low cure rates in the chronic stage of the disease and which have considerable toxicity. Posaconazole has shown trypanocidal activity in murine models.
Jean-Philippe Chippaux et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene, 107(1), 1-7 (2013-01-09)
A randomised, unblinded, clinical trial comparing two benznidazole regimens for congenital Chagas disease was carried out to determine whether simplification and reduction in the length of treatment could lead to better treatment compliance. This study was conducted in Santa Cruz
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持